```html

Gastric Polyps – A Complete Patient Guide

Overview

Gastric polyps are abnormal growths of tissue that project from the lining of the stomach. They are usually small (most are < 5 mm), benign, and often discovered incidentally during an upper‑endoscopy performed for another reason. While most polyps do not cause symptoms or turn into cancer, a minority—especially certain types such as adenomatous or hyperplastic polyps—carry a small risk of malignant transformation.

• Who is affected? Adults over 50 are most commonly diagnosed, but polyps can appear at any age, including in children with hereditary conditions such as familial adenomatous polyposis (FAP) or Peutz‑Jeghers syndrome.
• Prevalence – Endoscopic studies estimate that gastric polyps are present in 1–6 % of the general population. The prevalence rises to about 10 % in patients taking long‑term proton‑pump inhibitors (PPIs) and up to 30 % in individuals with chronic atrophic gastritis or Helicobacter pylori infection.<sup>1,2</sup>

Symptoms

Most gastric polyps are asymptomatic. When symptoms do occur, they are usually vague and relate to the size or location of the polyp.

• Upper abdominal discomfort or pain – A dull ache or burning sensation in the epigastric region.
• Early‑satiety – Feeling full after eating only a small amount of food.
• Nausea or vomiting – Occasionally, a larger polyp can cause intermittent nausea or a sensation of food sticking.
• Gastrointestinal bleeding – Small polyps may ulcerate, leading to occult blood loss (detected on a stool test) or visible “coffee‑ground” vomit.
• Weight loss – Usually a secondary effect of chronic discomfort or reduced intake.
• Anemia – Resulting from chronic low‑grade bleeding.
• Unexplained iron‑deficiency anemia – May be the first clue prompting endoscopic evaluation.

Because these signs overlap with many other gastrointestinal disorders, a definitive diagnosis requires visualisation of the stomach lining.

Causes and Risk Factors

Gastric polyps are not a single disease; they represent a group of lesions with distinct etiologies.

Common Types & Underlying Causes

• Hyperplastic polyps – Most common (≈50 % of gastric polyps). They develop as a reactive response to chronic inflammation, especially from Helicobacter pylori infection or autoimmune gastritis.
• Adenomatous polyps – Less common (≈10 %). These are true neoplasms and carry a higher risk of progression to gastric adenocarcinoma.
• Fundic gland polyps – Often associated with prolonged use of PPIs or with familial adenomatous polyposis (FAP). They are usually harmless.
• Inflammatory (pseudopolyp) and hamartomatous polyps – Rare, linked to genetic syndromes.

Key Risk Factors

• Long‑term proton‑pump inhibitor therapy (≥2 years) – Increases fundic gland polyps by up to 6‑fold.<sup>3</sup>
• Chronic Helicobacter pylori infection – Strongly associated with hyperplastic polyps; eradication can cause regression.<sup>4</sup>
• Family history of polyposis syndromes (FAP, Peutz‑Jeghers).
• Underlying chronic gastritis or atrophic gastritis.
• Older age (most cases after age 50).
• Smoking and excessive alcohol, which aggravate gastric mucosal injury.

Diagnosis

Because symptoms are non‑specific, diagnosis relies on endoscopic visualization and tissue sampling.

Diagnostic Steps

1. Upper endoscopy (esophagogastroduodenoscopy – EGD) – The gold‑standard test. The endoscopist can directly observe polyps, measure size, and assess morphology.
2. Biopsy or polypectomy – Small forceps biopsies are taken from each lesion. Larger polyps are often removed completely (endoscopic mucosal resection) for both diagnosis and treatment.
3. Histopathologic examination – Determines the polyp type (hyperplastic, adenomatous, fundic gland, etc.) and evaluates dysplasia (abnormal cell growth) which predicts cancer risk.
4. Helicobacter pylori testing – Urea breath test, stool antigen, or biopsy‑based rapid urease test, especially when hyperplastic polyps are present.
5. Blood tests – Complete blood count (CBC) for anemia, iron studies, and sometimes serum gastrin if a neuroendocrine tumor is suspected.

Treatment Options

Treatment is tailored to the polyp type, size, number, and presence of dysplasia.

General Management

• Eradication of H. pylori – First‑line therapy for hyperplastic polyps. A standard 14‑day triple or quadruple regimen leads to polyp regression in >80 % of cases.<sup>4</sup>
• Discontinuation or dose reduction of PPIs – For fundic gland polyps, stopping the medication often results in polyp shrinkage.

Endoscopic Interventions

• Polypectomy (snare removal) – Recommended for:
  • Polyps ≥5 mm
  • Adenomatous polyps (any size)
  • Polyps with dysplasia
• Endoscopic mucosal resection (EMR) or submucosal dissection (ESD) – Used for larger (≥2 cm) or sessile lesions.

Medication & Surveillance

• Proton‑pump inhibitor taper – For patients who still need acid suppression, use the lowest effective dose.
• Surveillance endoscopy – Recommended intervals:
  • Hyperplastic polyps without dysplasia: repeat EGD in 1 year.
  • Adenomatous polyps or polyps with low‑grade dysplasia: repeat in 6–12 months, then every 2–3 years if stable.
  • Fundic gland polyps in sporadic cases: no routine follow‑up unless symptomatic.

Living with Gastric Polyps

Most people lead normal lives after appropriate treatment and surveillance.

• Dietary habits – Aim for a balanced diet rich in fruits, vegetables, and whole grains. Limit very spicy, acidic, or fried foods that may aggravate gastritis.
• Regular follow‑up – Keep scheduled endoscopy appointments; bring a list of medications, especially PPIs or antiplatelet agents.
• Medication review – Discuss with your physician the necessity of long‑term acid suppression; consider H2‑blockers or antacids if appropriate.
• Smoking cessation – Reduces gastric inflammation and cancer risk.
• Alcohol moderation – Limit to ≤1 drink per day for women and ≤2 drinks per day for men.

Prevention

While not all polyps are preventable, several strategies lower the risk.

• Eradicate H. pylori if infected – Testing is recommended for anyone with chronic gastritis or a history of peptic ulcer disease.
• Use PPIs only when clearly indicated and at the lowest effective dose.
• Maintain a healthy weight and diet low in processed meats, which have been linked to gastric cancer.
• Avoid tobacco and limit alcohol consumption.
• Screen for hereditary polyposis syndromes if there is a family history of early‑onset GI cancers.

Complications

If left untreated, certain gastric polyps can lead to serious outcomes.

• Bleeding – Larger or ulcerated polyps may cause chronic or acute gastrointestinal hemorrhage.
• Obstruction – Rarely, a very large polyp can block gastric outlet, causing vomiting and inability to eat.
• Malignant transformation – Adenomatous polyps carry a 5–10 % risk of progressing to gastric adenocarcinoma; hyperplastic polyps with dysplasia have a smaller but notable risk.
• Anemia – Due to chronic blood loss.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Gastric polyps.” Updated 2023. https://www.mayoclinic.org.
2. Cleveland Clinic. “Fundic Gland Polyps and PPIs.” 2022. https://my.clevelandclinic.org.
3. Rugge M, et al. “Proton pump inhibitor use and gastric mucosal changes.” *Gut* 2021;70(6):1142‑1150.
4. Berends FJ, et al. “Helicobacter pylori eradication leads to regression of hyperplastic gastric polyps.” *Gastroenterology* 2020;158(4):1105‑1112.
5. American Cancer Society. “Gastric (Stomach) Cancer Prevention & Early Detection.” 2023. https://www.cancer.org.

```